Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Telix Pharmaceuticals Ltd. securities for the period between February 21, 2025, and August 28, 2025, due to alleged misleading statements made by the company regarding its business and operations [1][5]. Group 1: Lawsuit Details - The lawsuit claims that defendants made materially false and misleading statements about Telix's progress in prostate cancer therapeutic candidates and the quality of its supply chain and partners [5]. - Investors who purchased Telix securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by January 9, 2026, to represent other class members in the litigation [1][3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].
TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm